BAN2401 (lecanemab precursor, anti-protofibril Aβ antibody) in a Phase IIb dose-finding study showed dose-dependent amyloid lowering; Bayesian adaptive design provided early evidence of clinical slowing on ADCOMS in the highest-dose arm.

Evidence span

BAN2401 (lecanemab precursor, anti-protofibril Aβ antibody) in a Phase IIb dose-finding study showed dose-dependent amyloid lowering; Bayesian adaptive design provided early evidence of clinical slowing on ADCOMS in the highest-dose arm.

From reviewer:will-blair-bot

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Phase IIb EMERGE/ENGAGE precursor; n=856 early AD; six arms including BAN2401 10mg/kg biweekly; Bayesian adaptive 12-month design; primary: ADCOMS composite; amyloid PET secondary.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required